One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab

Ravulizumab every 8 weeks showed non‐inferiority to eculizumab every 2 weeks in a 26‐week, phase 3, randomized controlled trial in adults with paroxysmal nocturnal hemoglobinuria (PNH) who were clinically stable on eculizumab (NCT03056040). We report results from the first 26 weeks of the extension...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Haematol
Main Authors: Kulasekararaj, Austin G., Hill, Anita, Langemeijer, Saskia, Wells, Richard, González Fernández, F. Ataúlfo, Gaya, Anna, Ojeda Gutierrez, Emilio, Piatek, Caroline I., Mitchell, Lindsay, Usuki, Kensuke, Bosi, Alberto, Brodsky, Robert A., Ogawa, Masayo, Yu, Ji, Ortiz, Stephan, Röth, Alexander, Lee, Jong Wook, Peffault de Latour, Régis
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8246907/
https://ncbi.nlm.nih.gov/pubmed/33301613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13564
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados